Real-world efficacy of tirzepatide in patients with heart failure without diabetes

IF 3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology Pub Date : 2025-01-29 DOI:10.1016/j.cpcardiol.2025.102998

Silvio Nunes Augusto Jr , David Kaelber MD PhD MPH , W.H. Wilson Tang MD

{"title":"Real-world efficacy of tirzepatide in patients with heart failure without diabetes","authors":"Silvio Nunes Augusto Jr , David Kaelber MD PhD MPH , W.H. Wilson Tang MD","doi":"10.1016/j.cpcardiol.2025.102998","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown significant cardiovascular benefits in clinical trials. This study investigates the real-world impact of tirzepatide on heart failure (HF) outcomes, leveraging data from the TriNetX platform.</div></div><div><h3>Methods</h3><div>Using data from January 1, 2013, to December 01, 2024, we conducted a propensity-matched analysis of two cohorts of patients with HF without diabetes, where the only difference was the use of tirzepatide. The primary outcome was the incidence of acute heart failure (acute HF), with secondary outcomes including major adverse cardiovascular events (MACE), chronic kidney disease (CKD), stroke, and coronary arterial disease (CAD).</div></div><div><h3>Results</h3><div>After propensity-matching, 897 patients were compared between the two cohorts in a 4-year follow-up, showing that untreated patients were at higher risk of incident acute HF (HR: 3.12, 95 %CI = 2.240–4.349, log-rank <em>p</em> < 0.001) and MACE (HR: 3.57, 95 %CI = 2.32–5.48, log-rank <em>p</em> < 0.001). Stroke (HR: 2.796, 95 %CI = 1.353–5.776, log-rank <em>p</em> < 0.01), CKD (HR: 1.48, 95 %CI: 1.08–2.03, log-rank <em>p</em> = 0.015), and CAD (HR: 1.474, 95 %CI,1.169–1.859, log-rank <em>p</em> = 0.001) outcomes also favored the treatment cohort.</div></div><div><h3>Conclusion</h3><div>Tirzepatide presents a promising therapeutic option for managing heart failure, with significant metabolic and cardiovascular benefits. These real-world findings reinforce its potential role as a transformative treatment in improving clinical outcomes and quality of life for patients with HF without diabetes.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 4","pages":"Article 102998"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0146280625000210","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown significant cardiovascular benefits in clinical trials. This study investigates the real-world impact of tirzepatide on heart failure (HF) outcomes, leveraging data from the TriNetX platform.

Methods

Using data from January 1, 2013, to December 01, 2024, we conducted a propensity-matched analysis of two cohorts of patients with HF without diabetes, where the only difference was the use of tirzepatide. The primary outcome was the incidence of acute heart failure (acute HF), with secondary outcomes including major adverse cardiovascular events (MACE), chronic kidney disease (CKD), stroke, and coronary arterial disease (CAD).

Results

After propensity-matching, 897 patients were compared between the two cohorts in a 4-year follow-up, showing that untreated patients were at higher risk of incident acute HF (HR: 3.12, 95 %CI = 2.240–4.349, log-rank p < 0.001) and MACE (HR: 3.57, 95 %CI = 2.32–5.48, log-rank p < 0.001). Stroke (HR: 2.796, 95 %CI = 1.353–5.776, log-rank p < 0.01), CKD (HR: 1.48, 95 %CI: 1.08–2.03, log-rank p = 0.015), and CAD (HR: 1.474, 95 %CI,1.169–1.859, log-rank p = 0.001) outcomes also favored the treatment cohort.

Conclusion

Tirzepatide presents a promising therapeutic option for managing heart failure, with significant metabolic and cardiovascular benefits. These real-world findings reinforce its potential role as a transformative treatment in improving clinical outcomes and quality of life for patients with HF without diabetes.

查看原文本刊更多论文

替扎帕肽对无糖尿病心衰患者的实际疗效

背景：tizepatide是一种葡萄糖依赖性胰岛素性多肽（GIP）和胰高血糖素样肽-1 （GLP-1）受体的双重激动剂，在临床试验中显示出显著的心血管益处。本研究利用TriNetX平台的数据，调查了替西肽对心力衰竭（HF）结局的现实影响。方法：使用2013年1月1日至2024年12月1日的数据，我们对两组无糖尿病的HF患者进行了倾向匹配分析，其中唯一的区别是使用替西帕肽。主要结局是急性心力衰竭（急性HF）的发生率，次要结局包括主要不良心血管事件（MACE）、慢性肾脏疾病（CKD）、中风和冠状动脉疾病（CAD）。结果：经过倾向匹配，在4年的随访中比较了两组897例患者，结果显示未经治疗的患者发生急性HF的风险更高（HR: 3.12, 95%CI = 2.240-4.349,log-rank p）。结论：替西帕肽是治疗心力衰竭的一种有希望的治疗选择，具有显著的代谢和心血管益处。这些现实世界的发现强化了它作为一种变革性治疗在改善无糖尿病心衰患者的临床结果和生活质量方面的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Problems in Cardiology 医学-心血管系统

CiteScore

4.80

自引率

2.40%

发文量

392

审稿时长

6 days

期刊介绍： Under the editorial leadership of noted cardiologist Dr. Hector O. Ventura, Current Problems in Cardiology provides focused, comprehensive coverage of important clinical topics in cardiology. Each monthly issues, addresses a selected clinical problem or condition, including pathophysiology, invasive and noninvasive diagnosis, drug therapy, surgical management, and rehabilitation; or explores the clinical applications of a diagnostic modality or a particular category of drugs. Critical commentary from the distinguished editorial board accompanies each monograph, providing readers with additional insights. An extensive bibliography in each issue saves hours of library research.